Advertisement

Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease

  • Author Footnotes
    1 Indicates equal contribution.
    Arash Rashidi
    Correspondence
    Address correspondence to Arash Rashidi, MD, Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, 11100 Euclid Ave, Cleveland, OH 44106.
    Footnotes
    1 Indicates equal contribution.
    Affiliations
    Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Cleveland, OH
    Search for articles by this author
  • Author Footnotes
    1 Indicates equal contribution.
    Pranav S. Garimella
    Footnotes
    1 Indicates equal contribution.
    Affiliations
    Division of Nephrology and Hypertension, University of California San Diego, La Jolla, CA
    Search for articles by this author
  • Author Footnotes
    1 Indicates equal contribution.
    Abdullah Al-Asaad
    Footnotes
    1 Indicates equal contribution.
    Affiliations
    Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Cleveland, OH
    Search for articles by this author
  • Author Footnotes
    1 Indicates equal contribution.
    Talar Kharadjian
    Footnotes
    1 Indicates equal contribution.
    Affiliations
    Division of Nephrology and Hypertension, University of California San Diego, La Jolla, CA
    Search for articles by this author
  • Author Footnotes
    1 Indicates equal contribution.
    Mariela Navarro Torres
    Footnotes
    1 Indicates equal contribution.
    Affiliations
    Department of Medicine/Division of Nephrology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
    Search for articles by this author
  • Jyotsana Thakkar
    Affiliations
    Department of Medicine/Division of Nephrology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
    Search for articles by this author
  • Author Footnotes
    1 Indicates equal contribution.
      Anemia is a common medical problem among patients with cancer and chronic kidney disease (CKD). Although anemia in patients with CKD is often treated with iron and erythropoietin-stimulating agents, there are controversies with regard to the use of erythropoietin-stimulating agents in cancer patients. In this article, we review the treatment of anemia in patients with cancer and CKD, in addition to summarizing the current guidelines in treatment of anemia in these patients.

      Graphical abstract

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Groopman J.E.
        • Itri L.M.
        Chemotherapy-induced anemia in adults: incidence and treatment.
        J Natl Cancer Inst. 1999; 91: 1616-1634
        • Barrett-Lee P.J.
        • Bailey N.P.
        • O'Brien M.E.
        • Wager E.
        Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy.
        Br J Cancer. 2000; 82: 93-97
        • Skillings J.R.
        • Sridhar F.G.
        • Wong C.
        • Paddock L.
        The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study.
        Am J Clin Oncol. 1993; 16: 22-25
        • Xu H.
        • Xu L.
        • Page J.H.
        • et al.
        Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010-2013.
        Clin Epidemiol. 2016; 8: 61-71
        • Abdel-Razeq H.
        • Hashem H.
        Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia.
        Crit Rev Oncol Hematol. 2020; 145: 102837
        • Jacobson L.O.
        • Goldwasser E.
        • Fried W.
        • Plzak L.
        Role of the kidney in erythropoiesis.
        Nature. 1957; 179: 633-634
        • Maccio A.
        • Madeddu C.
        • Gramignano G.
        • et al.
        The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study.
        Haematologica. 2015; 100: 124-132
        • Erslev A.
        Humoral regulation of red cell production.
        Blood. 1953; 8: 349-357
        • Babitt J.L.
        • Lin H.Y.
        Mechanisms of anemia in CKD.
        J Am Soc Nephrol. 2012; 23: 1631-1634
        • KDIGO
        Clinical practice guideline for anemia in chronic kidney disease.
        Kidney Int Suppl. 2012; 2: 283-287
        • Aapro M.
        • Osterborg A.
        • Gascon P.
        • Ludwig H.
        • Beguin Y.
        Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron.
        Ann Oncol. 2012; 23: 1954-1962
        • Tran T.N.
        • Eubanks S.K.
        • Schaffer K.J.
        • Zhou C.Y.
        • Linder M.C.
        Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron.
        Blood. 1997; 90: 4979-4986
        • Goodnough L.T.
        • Nemeth E.
        • Ganz T.
        Detection, evaluation, and management of iron-restricted erythropoiesis.
        Blood. 2010; 116: 4754-4761
        • Thomas D.W.
        • Hinchliffe R.F.
        • Briggs C.
        • et al.
        Guideline for the laboratory diagnosis of functional iron deficiency.
        Br J Haematol. 2013; 161: 639-648
        • Collister D.
        • Komenda P.
        • Hiebert B.
        • et al.
        The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis.
        Ann Intern Med. 2016; 164: 472-478
        • Spinowitz B.
        • Pecoits-Filho R.
        • Winkelmayer W.C.
        • et al.
        Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.
        J Med Econ. 2019; 22: 593-604
        • Guedes M.
        • Guetter C.R.
        • Erbano L.H.O.
        • et al.
        Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis.
        BMC Nephrol. 2020; 21: 259
        • Eschbach J.W.
        • Cook J.D.
        • Scribner B.H.
        • Finch C.A.
        Iron balance in hemodialysis patients.
        Ann Intern Med. 1977; 87: 710-713
        • Stancu S.
        • Barsan L.
        • Stanciu A.
        • Mircescu G.
        Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?.
        Clin J Am Soc Nephrol. 2010; 5: 409-416
        • Gupta A.
        • Lin V.
        • Guss C.
        • Pratt R.
        • Ikizler T.A.
        • Besarab A.
        Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.
        Kidney Int. 2015; 88: 1187-1194
        • Dahl N.V.
        • Kaper R.F.
        • Strauss W.E.
        • Corvino F.A.
        • Zivkovic M.
        Cost-effectiveness analysis of intravenous ferumoxytol for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease in the USA.
        Clinicoecon Outcomes Res. 2017; 9: 557-567
        • Macdougall I.C.
        • Bock A.H.
        • Carrera F.
        • et al.
        FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
        Nephrol Dial Transpl. 2014; 29: 2075-2084
        • Agarwal R.
        • Kusek J.W.
        • Pappas M.K.
        A randomized trial of intravenous and oral iron in chronic kidney disease.
        Kidney Int. 2015; 88: 905-914
        • Shepshelovich D.
        • Rozen-Zvi B.
        • Avni T.
        • Gafter U.
        • Gafter-Gvili A.
        Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an Updated systematic review and meta-analysis.
        Am J Kidney Dis. 2016; 68: 677-690
        • Macdougall I.C.
        • White C.
        • Anker S.D.
        • et al.
        Intravenous iron in patients undergoing maintenance hemodialysis.
        N Engl J Med. 2019; 380: 447-458
        • Hougen I.
        • Collister D.
        • Bourrier M.
        • et al.
        Safety of intravenous iron in dialysis: a systematic review and meta-analysis.
        Clin J Am Soc Nephrol. 2018; 13: 457-467
        • Ishida J.H.
        • Marafino B.J.
        • McCulloch C.E.
        • et al.
        Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection.
        Clin J Am Soc Nephrol. 2015; 10: 1799-1805
        • Karaboyas A.
        • Morgenstern H.
        • Pisoni R.L.
        • et al.
        Association between serum ferritin and mortality: findings from the USA, Japan and European dialysis outcomes and practice patterns study.
        Nephrol Dial Transpl. 2018; 33: 2234-2244
        • Petrelli F.
        • Borgonovo K.
        • Cabiddu M.
        • Lonati V.
        • Barni S.
        Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.
        J Cancer Res Clin Oncol. 2012; 138: 179-187
        • Rodgers G.M.
        • Gilreath J.A.
        The role of intravenous iron in the treatment of anemia associated with cancer and chemotherapy.
        Acta Haematol. 2019; 142: 13-20
        • Schrijvers D.
        • De Samblanx H.
        • Roila F.
        • Group E.G.W.
        Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use.
        Ann Oncol. 2010; 21: 244-247
        • Aapro M.
        • Beguin Y.
        • Bokemeyer C.
        • et al.
        Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.
        Ann Oncol. 2018; 29: iv96-iv110
        • Prabhakar N.R.
        • Semenza G.L.
        Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2.
        Physiol Rev. 2012; 92: 967-1003
        • Provenzano R.
        • Fishbane S.
        • Szczech L.
        • et al.
        Pooled analysis of roxadustat for anemia in patients with kidney failure incident to dialysis.
        Kidney Int Rep. 2021; 6: 613-623
        • Coyne D.W.
        • Roger S.D.
        • Shin S.K.
        • et al.
        Roxadustat for CKD-related anemia in non-dialysis patients.
        Kidney Int Rep. 2021; 6: 624-635
        • Chrysant S.G.
        • Chrysant G.S.
        The current status of homocysteine as a risk factor for cardiovascular disease: a mini review.
        Expert Rev Cardiovasc Ther. 2018; 16: 559-565
        • Mann J.F.
        • Sheridan P.
        • McQueen M.J.
        • et al.
        Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study.
        Nephrol Dial Transpl. 2008; 23: 645-653
        • Latcha S.
        Anemia management in cancer patients with chronic kidney disease.
        Semin Dial. 2019; 32: 513-519
        • Semenza G.L.
        Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics.
        Oncogene. 2010; 29: 625-634
        • Seeley T.W.
        • Sternlicht M.D.
        • Klaus S.J.
        • Neff T.B.
        • Liu D.Y.
        Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.
        Hypoxia (Auckl). 2017 Mar 10; 5: 1-9
        • Zou S.
        • Stramer S.L.
        • Dodd R.Y.
        Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations.
        Transfus Med Rev. 2012; 26: 119-128
        • Hung S.Y.
        • Lin T.M.
        • Chang M.Y.
        • et al.
        Risk factors of sensitization to human leukocyte antigen in end-stage renal disease patients.
        Hum Immunol. 2014; 75: 531-535
      1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
        Kidney Int Suppl. 2013; 3: 1-150
        • Fissell R.B.
        • Bragg-Gresham J.L.
        • Gillespie B.W.
        • et al.
        International variation in vitamin prescription and association with mortality in the dialysis outcomes and practice patterns study (DOPPS).
        Am J Kidney Dis. 2004; 44: 293-299
        • Bohlius J.
        • Bohlke K.
        • Castelli R.
        • et al.
        Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.
        Blood Adv. 2019; 3: 1197-1210
        • Kenar G.
        • Koksoy E.B.
        • Urun Y.
        • Utkan G.
        Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer.
        Support Care Cancer. 2020; 28: 5235-5242
        • Pfeffer M.A.
        • Burdmann E.A.
        • Chen C.Y.
        • et al.
        A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
        N Engl J Med. 2009; 361: 2019-2032
        • Henke M.
        • Laszig R.
        • Rube C.
        • et al.
        Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.
        Lancet. 2003; 362: 1255-1260
        • Imai E.
        • Yamamoto R.
        • Suzuki H.
        • Watanabe T.
        Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins.
        Clin Exp Nephrol. 2010; 14: 445-452
        • Tonia T.
        • Mettler A.
        • Robert N.
        • et al.
        Erythropoietin or darbepoetin for patients with cancer.
        Cochrane Database Syst Rev. 2012; 12: CD003407
        • Aapro M.
        • Jelkmann W.
        • Constantinescu S.N.
        • Leyland-Jones B.
        Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.
        Br J Cancer. 2012; 106: 1249-1258
        • Arcasoy M.O.
        The non-haematopoietic biological effects of erythropoietin.
        Br J Haematol. 2008; 141: 14-31
        • Watanabe D.
        • Suzuma K.
        • Matsui S.
        • et al.
        Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.
        N Engl J Med. 2005; 353: 782-792
        • Hu W.
        • Zhang Y.
        • Jiang Z.
        • et al.
        The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer.
        Tumour Biol. 2016; 37: 11523-11533
        • Wu P.
        • Zhang N.
        • Wang X.
        • et al.
        The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.
        PloS one. 2012; 7: e45122
        • Reinbothe S.
        • Larsson A.M.
        • Vaapil M.
        • et al.
        EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
        Biochem Biophys Res Commun. 2014; 445: 163-169
        • Overgaard J.
        • Hoff C.M.
        • Hansen H.S.
        • et al.
        Dahanca 10 - effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
        Radiother Oncol. 2018; 127: 12-19
        • Veis R.
        Clinical applications of appliance therapy in general dental practice, Part 3. Minor tooth movement for adults.
        Dent Today. 2003; 22 (quiz 121): 116-120
        • Leyland-Jones B.
        • Bondarenko I.
        • Nemsadze G.
        • et al.
        A randomized, open-label, multicenter, phase III study of epoetin alfa versus best Standard of care in anemic patients with Metastatic breast cancer receiving Standard chemotherapy.
        J Clin Oncol. 2016; 34: 1197-1207
        • Rosenzweig M.Q.
        • Bender C.M.
        • Lucke J.P.
        • Yasko J.M.
        • Brufsky A.M.
        The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events.
        J Pain Symptom Manage. 2004; 27: 185-190
        • Khorana A.A.
        • Francis C.W.
        • Culakova E.
        • Kuderer N.M.
        • Lyman G.H.
        Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.
        J Thromb Haemost. 2007; 5: 632-634
        • Wun T.
        • Law L.
        • Harvey D.
        • Sieracki B.
        • Scudder S.A.
        • Ryu J.K.
        Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin.
        Cancer. 2003; 98: 1514-1520
        • Seliger S.L.
        • Zhang A.D.
        • Weir M.R.
        • et al.
        Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease.
        Kidney Int. 2011; 80: 288-294
        • Bohlius J.
        • Bohlke K.
        • Castelli R.
        • et al.
        Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH Clinical Practice Guideline Update.
        J Clin Oncol. 2019; 37: 1336-1351
        • KDOQI
        • National Kidney Foundation
        KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.
        Am J Kidney Dis. 2006; 47: S11-S145